In a significant advance for drug discovery and biologics development, acCELLerate, a specialist in manufacturing assay-ready frozen cells, has forged a strategic partnership with ATCC, a globally renowned biological resource and standards organization. This new collaboration aims to deliver bespoke cell banking solutions by leveraging ATCC’s extensive portfolio of authenticated cell lines, augmented by acCELLerate’s cutting-edge cryopreservation expertise and scalable cell banking technologies. The alliance positions researchers within pharmaceutical and biotechnology sectors to access rigorously prepared custom cell banks, including Master Cell Banks (MCBs), Working Cell Banks (WCBs), and ready-to-use instaCELL assays designed explicitly for high-throughput bioassays and potency testing in biologics.
Cell-based assays have become cornerstone technologies in preclinical drug development and quality control contexts due to their ability to recapitulate complex biological processes. However, variability in cell culture conditions, passage number, and genetic drift can pose substantial challenges to assay reproducibility and reliability. Recognizing these bottlenecks, acCELLerate’s bespoke cell banking services adhere strictly to good cell culture practices (gccp) that harmonize with ATCC’s culture quality standards, ensuring that biopharmaceutical researchers receive cell materials with uncompromised identity, viability, and functional integrity.
At the core of this partnership is acCELLerate’s proprietary assay-ready instaCELL format. These frozen cells are meticulously cryopreserved in a reagent-like state, enabling direct use in bioassays without the need for extensive culture expansion. This innovation dramatically reduces cell culture-related variability and significantly streamlines workflows in drug screening and biologics potency evaluations. By utilizing instaCELLs derived from authenticated ATCC lines, researchers can substantially improve assay precision, accelerating the transition from discovery-phase experimentation to robust preclinical validation.
The scalability and adaptability of the multi-tiered cell banking strategy offered by acCELLerate introduce unprecedented flexibility into research supply chains. Master Cell Banks serve as the foundational repository of cell material, from which Working Cell Banks are derived to support routine assay production. The integration of assay ready instaCELLs provides an additional tier optimized for immediate experimental deployment. This structured approach to cell banking aligns with regulatory expectations and enhances traceability, ultimately fostering confidence in downstream data generated for regulatory submissions.
Dr. Oliver Wehmeier, Managing Director of acCELLerate, emphasizes the transformative potential of this collaboration, explaining that it effectively removes the burden of in-house cell line maintenance for research organizations, freeing scientific teams to focus on experimental design and data analysis. “Our capability to produce custom cell banks from ATCC’s authenticated lines under strict quality parameters ensures reproducibility at scale and supports diverse stages of drug discovery, from initial screening through to quality control bioassays,” he notes. This partnership not only expedites research timelines but also mitigates risks associated with cell line contamination and misidentification.
ATCC, with over a century of leadership as a global biological materials resource, brings to the table an unparalleled catalogue of validated cell lines spanning a broad spectrum of human and animal models. Their comprehensive authentication processes, including genetic profiling and pathogen testing, set the gold standard in biological reference materials. Dr. Ruth Cheng, President and CEO of ATCC, highlights the strategic alignment between the organizations: “The synergy between acCELLerate’s cell banking expertise and our authenticated repository expedites access to reliable cell models, which are foundational for the acceleration of biopharmaceutical innovations globally.”
This newly announced collaboration embodies a forward-thinking approach to supporting the biopharma sector by merging robust quality management with technological innovation. Assay-ready cells from ATCC-derived custom banks are poised to transform workflows associated with cancer cell line studies, immuno-oncology models like Jurkat cells, and various transfected and epithelial cell lines critical for translational research. The availability of serum-free media formulations tailored for these cells further enhances their utility in in vitro assays by minimizing variability linked to animal-derived components.
Beyond drug discovery, the impact of this partnership extends to quality control and regulatory environments where reproducibility and traceability are paramount. Large-scale GMP-compliant cell banking facilitates consistent bioassay performance in batch release and stability testing of biologics. By delivering defined, validated cell materials, acCELLerate and ATCC jointly contribute to establishing more rigorous assay standards that support regulatory compliance and product safety.
The strategic integration of cell line authentication and cell banking services also addresses the global need for standardized biological models. With diverse research efforts spanning academic, pharmaceutical, and industrial sectors, consistent access to high-quality, reproducible cell banks is critical. This collaboration represents a model for how cutting-edge technology providers and biological repositories can partner to streamline complex supply chains and accelerate translational medicine.
As biologics and personalized medicine continue to evolve, the demand for robust preclinical tools intensifies. Customized cell banks and assay-ready cells that deliver high fidelity biological responses are essential to accurately model disease pathways and therapeutic responses. The acCELLerate-ATCC collaboration exemplifies the kind of innovation ecosystem necessary to meet this demand, fostering efficiency, reducing experimental variability, and propelling biopharma R&D forward.
Importantly, the partnership underscores the critical role of cryopreservation science in preserving cellular phenotypes and function over extended storage periods. acCELLerate’s validated cryopreservation protocols ensure minimal cell stress and maintain assay sensitivity, addressing a crucial technical challenge that can otherwise compromise experimental outcomes. This technical rigor equips researchers with reliable reagents capable of supporting complex bioassays, including potency evaluation of monoclonal antibodies, cell-based immunogenicity testing, and high-content screening applications.
In conclusion, the alliance between acCELLerate and ATCC sets a new standard for bespoke cell banking services fortified by authenticated biological resources. By offering researchers efficient access to high-quality, assay-ready cell banks, the partnership accelerates drug discovery timelines and elevates assay reproducibility to meet the demands of modern biopharmaceutical development. This collaboration is poised to become a cornerstone resource underpinning innovative biologics research worldwide.
Subject of Research: Custom cell banking and assay-ready cell production for drug discovery and biologics potency testing.
Article Title: acCELLerate and ATCC Partner to Revolutionize Custom Cell Banking for Biopharma Research
News Publication Date: Not specified.
Web References: Not specified.
References: Not specified.
Image Credits: acCELLerate
Keywords: Cell lines, Cancer cell lines, Jurkat cells, Eukaryotic cells, Transfected cells, Keratinocytes, Cell cultures, Tissue cultures, Serum free media, In vitro assays, Animal cells, Epithelial cells, Cell proliferation
